U.S. Markets closed

Repros Therapeutics forms advisory board for Androxal

Repros Therapeutics announced the formation of an international, multi-disciplinary, clinical advisory board to help maximize the commercial opportunity for Androxal. In parallel with the formation of this advisory board, an additional advisory board comprising primarily endocrinologists and primary care physicians is being assembled over the next several weeks. The company said it is anticipated that during the coming months while Androxal continues to undergo its current Phase 3 clinical trials and regulatory review, a number of advisory board meetings will convene.